Royal Philips’ sales rebounded in the third quarter of 2020, growing 10% to €4.98bn ($5.83bn) on a comparable basis, after a coronavirus-affected second quarter which saw comparable sales drop by 6%.
The connected care business once again outperformed both diagnosis and treatment (D&T), and personal health, expanding by 42% in Q3 after being the sole growth area in Q2. Double-digit growth...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?